Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052767 | 0.83 | ENPP2 (0.50) | ENPP2PTGS2PTGS1PKM | |
| SCHEMBL2349931 | 0.78 | PSIP1 (0.50) | PKM | |
| SCHEMBL11547843 | 0.78 | HTT (0.58) | ENPP2PTGS2PTGS1 | |
| SCHEMBL1695070 | 0.77 | ALDH1A1 (0.64) | PTGS2 | |
| SCHEMBL2376239 | 0.77 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL4050348 | 0.77 | SMN1; SMN2 (0.68) | PKM | |
| SCHEMBL14331939 | 0.77 | MMP13 (0.38) | PKM | |
| SCHEMBL11986371 | 0.76 | PKM (0.70) | PTGS2PTGS1PKM | |
| SCHEMBL280156 | 0.76 | PKM (0.70) | PTGS2PTGS1PKM | |
| SCHEMBL934211 | 0.75 | DDB1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| CN-119013265-A | GLUT9 heterocyclic inhibitors for the treatment of disease | 爱尔兰好利恩治疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118702608-A | Novel synthesis method of eremophilone | 重庆圣华曦药业股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-113999180-B | Quinazoline compound, intermediate, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117736207-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-115362003-B | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-117500496-A | Pyrimidine and pyridinamine compounds and their use in the treatment of diseases | 艾匹根生物技术有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117396472-A | SOS1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2004000811-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1369421-A1 | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LIMITED (GB) | 2003-12-10 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1032575-B1 | 2,3-DIARYL-PYRAZOLO(1,5-B)PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LTD (GB) | 2003-07-23 | — | — | EP | disclosed |
| US-20030040517-A1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibirors | SMITHKLINE BEECHAM CORPORATION | 2003-02-27 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-20030008872-A1 | 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | BESWICK PAUL JOHN (GB) | 2003-01-09 | — | — | US | disclosed |
| US-6451794-B1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-09-17 | — | — | US | disclosed |
| EP-1032575-A1 | 2,3-DIARYL-PYRAZOLO(1,5-B)PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999012930-A1 | 2,3-DIARYL-PYRAZOLO[1,5-B]PYRIDAZINES DERIVATIVES, THEIR PREPA RATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | ENPP2 255/4885PTGS2 680/4885PTGS1 629/4885 |
| US-20030008872-A1 | 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | PTGS1, CBR1, PTGER1 | ENPP2 2037/4885PTGS2 6/4885PTGS1 1/4885 |
| US-20030040517-A1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibirors | CBR1, CRHR1, CRHR2 | ENPP2 2610/4885PTGS2 17/4885PTGS1 5/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | ENPP2 2267/4885PTGS2 1423/4885PTGS1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.